Navigation Links
New Drug May Trim Insulin Injections to Just 3 a Week
Date:3/9/2011

By Randy Dotinga
HealthDay Reporter

WEDNESDAY, March 9 (HealthDay News) -- A preliminary study reports that people with diabetes were able to get injections of a new insulin drug just three times a week without major ill effects.

The findings still need to be confirmed in another phase of research, and it's not clear how much the drug would cost if it were approved for this use.

But those caveats aside, the study raises the possibility that people with type 2 diabetes might be able to escape the difficult regimens that require them to inject themselves with insulin as often as four times a day.

"The presumption here is if you use a medication less frequently, then people are more likely to take it and remember it, especially as we multitask and try to do so many things every day," said Dr. Yogish C. Kudva, a diabetes specialist and consultant at the Mayo Clinic in Rochester, Minn., who co-wrote a commentary accompanying publication of the study in the March 10 online edition of The Lancet.

Many people with type 2 diabetes take insulin through injections to control their blood sugar level, but it's not a perfect treatment. Insulin can cause weight gain and attacks of high or low blood sugar.

Alternative forms of insulin are currently being tested, as are other types of diabetes drugs. The new study was a phase 2 trial to test degludec, an experimental insulin drug made by Novo Nordisk, which funded the research.

For the study, 245 adults with diabetes -- none of whom had begun taking insulin -- were randomly assigned to take an existing form of insulin daily or to take degludec, either in a daily dose or three-times-a-week doses.

The researchers reported that, over a 16-week period, the three-times-a-week doses controlled blood sugar about as well as the other treatments.

Diabetes specialist Dr. Vivian Fonseca, who chairs the endocrinology section at Tulane University Health Sciences Center, cautioned that more research is needed to determine if people who take the drug will face a higher risk of low blood sugar.

That's a major problem for people who currently take insulin medications, she said, as is the unpredictability of the drugs. "You give the same dose to the same person every day, and the next morning you get a different result," Fonseca said. "That is challenging for patients."

It typically takes years for a drug to go through research and get approval from the U.S. government. The three-times-a-week degludec needs just one more phase of research, however, meaning that it could be on the market fairly soon if it's found to be effective. There's no indication of how much it would cost, although Kudva said it's fair to assume that it will be more expensive than insulin is today.

But one thing remains clear, Kudva said: "The most effective treatment for diabetes, a treatment that is worth doing throughout life, is attention to diet and exercise and working on one's weight. These are difficult to achieve, but even as every new medication comes, there's no getting away from that."

More information

The U.S. National Diabetes Information Clearinghouse has more on diabetes medicine.

SOURCES: Yogish C. Kudva, M.B.B.S., consultant, Mayo Clinic, Rochester, Minn.; Vivian Fonseca, M.D., professor, medicine and pharmacology, and chief, endocrinology section, Tulane University Health Sciences Center, New Orleans; March 10, 2011, The Lancet, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hormone Outperforms Insulin in Diabetic Mice
2. Experts call for further research into the relationship between insulin therapy and cancer
3. More Info Needed on Problems With Insulin Pumps
4. New Inhaled Insulin Shows Promise for Diabetes
5. Jekyll and Hyde Factor May Control Insulin Function
6. Study Finds That Insulin-Producing Beta Cells Can Be Reborn
7. One Sleepless Night Ups Insulin Resistance
8. Mayo-led research team develop agents that keep insulin working longer
9. New pathway to cheap insulin
10. Nicer than needles: Insulin pills for diabetes finally in clinical trials
11. Diabetic potential to create own insulin
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug May Trim Insulin Injections to Just 3 a Week
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... NJ, is a diverse community of over 1,000 passionate employees, caregivers, volunteers, thought ... After Parker at Stonegate changed ownership, it was time to refresh the carpeting ...
(Date:8/18/2017)... (PRWEB) , ... August 19, 2017 , ... ... Tourism Authority of Thailand presided over the Amazing Thailand Health and Wellness Tourism ... Thailand. , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business at ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the importance of ... individuals with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... financial consultations to communities throughout the greater DC region, is inaugurating a “New ... of rescuing local animals and training them to be companions for veterans in ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology: